Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

July 6, 2022 Biz People

BioXcel Therapeutics names new board member ahead of drug launch

Photo | Contributed Michael P. Miller

Bioscience veteran Michael P. Miller was named to the board of directors of BioXcel Therapeutics, the New Haven-based company announced this week.

Most recently an executive vice president at Ireland-based Jazz Pharmaceuticals, Miller has four decades of strategic leadership and commercial growth experience in the pharmaceutical industry, BioXcel said in a statement. 

BioXcel CEO Vimal Mehta said, “We are pleased to welcome Mike to our board and believe his deep commercial and market access expertise will be invaluable.”

Miller’s commercial expertise was singled out as BioXcel prepares to launch IGALMI, its sublingual film formulation of its drug for agitation associated with schizophrenia or bipolar disorder in adults. The FDA approved IGALMI in April. 

“Mike’s significant industry experience with initial and expanded-indication product launches, along with his development and operational knowledge in both neuroscience and oncology, will be a critical resource to the company at this key time of growth, as we optimize our commercial capabilities and continue to advance our pipeline,” Mehta said. 

Prior to Jazz, Miller served in senior executive management roles at VIVUS, Genentech (until acquisition by Roche), Connetics Corp. and ALZA Corp. He holds a B.S. in finance from the University of San Francisco and an MBA from San Francisco State University.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF